Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Epidemiology of Ebola Virus Disease in the Western Area Region of Sierra Leone, 2014-2015.

Lamunu M, Olu OO, Bangura J, Yoti Z, Samba TT, Kargbo DK, Dafae FM, Raja MA, Sempira N, Ivan ML, Sing A, Kurti-George F, Worku N, Mitula P, Ganda L, Samupindi R, Conteh R, Kamara KB, Muraguri B, Kposowa M, Charles J, Mugaga M, Dye C, Banerjee A, Formenty P, Kargbo B, Aylward RB.

Front Public Health. 2017 Mar 2;5:33. doi: 10.3389/fpubh.2017.00033. eCollection 2017.

2.

Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days.

Diallo B, Sissoko D, Loman NJ, Bah HA, Bah H, Worrell MC, Conde LS, Sacko R, Mesfin S, Loua A, Kalonda JK, Erondu NA, Dahl BA, Handrick S, Goodfellow I, Meredith LW, Cotten M, Jah U, Guetiya Wadoum RE, Rollin P, Magassouba N, Malvy D, Anglaret X, Carroll MW, Aylward RB, Djingarey MH, Diarra A, Formenty P, Keïta S, Günther S, Rambaut A, Duraffour S.

Clin Infect Dis. 2016 Nov 15;63(10):1353-1356. Epub 2016 Sep 1.

3.

Spatial Dynamics and High Risk Transmission Pathways of Poliovirus in Nigeria 2001-2013.

Mangal TD, Aylward RB, Shuaib F, Mwanza M, Pate MA, Abanida E, Grassly NC.

PLoS One. 2016 Sep 26;11(9):e0163065. doi: 10.1371/journal.pone.0163065. eCollection 2016.

4.

Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication.

Blake IM, Chenoweth P, Okayasu H, Donnelly CA, Aylward RB, Grassly NC.

Emerg Infect Dis. 2016 Mar;22(3):449-56. doi: 10.3201/eid2203.151394.

5.

A New Method for Estimating the Coverage of Mass Vaccination Campaigns Against Poliomyelitis From Surveillance Data.

O'Reilly KM, Cori A, Durry E, Wadood MZ, Bosan A, Aylward RB, Grassly NC.

Am J Epidemiol. 2015 Dec 1;182(11):961-70. doi: 10.1093/aje/kwv199. Epub 2015 Nov 14.

6.

Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.

Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB.

Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.

PMID:
26388534
7.

Affordable inactivated poliovirus vaccine: strategies and progress.

Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S459-64. doi: 10.1093/infdis/jiu128. Review.

PMID:
25316868
8.

The new polio eradication end game: rationale and supporting evidence.

Sutter RW, Platt L, Mach O, Jafari H, Aylward RB.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S434-8. doi: 10.1093/infdis/jiu222. Review.

PMID:
25316865
9.

A world without polio.

Cochi SL, Jafari HS, Armstrong GL, Sutter RW, Linkins RW, Pallansch MA, Kew O, Aylward RB.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S1-4. doi: 10.1093/infdis/jiu383. No abstract available.

PMID:
25316822
10.

Polio eradication. Efficacy of inactivated poliovirus vaccine in India.

Jafari H, Deshpande JM, Sutter RW, Bahl S, Verma H, Ahmad M, Kunwar A, Vishwakarma R, Agarwal A, Jain S, Estivariz C, Sethi R, Molodecky NA, Grassly NC, Pallansch MA, Chatterjee A, Aylward RB.

Science. 2014 Aug 22;345(6199):922-5. doi: 10.1126/science.1255006.

11.

Making history: from a public health emergency to a polio-free world.

Aylward RB.

Bull World Health Organ. 2014 Jul 1;92(7):466. doi: 10.2471/BLT.14.142273. No abstract available.

12.

Key issues in the persistence of poliomyelitis in Nigeria: a case-control study.

Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, Grassly NC.

Lancet Glob Health. 2014 Feb;2(2):e90-7. doi: 10.1016/S2214-109X(13)70168-2. Epub 2014 Jan 23.

13.

Integration, community engagement, and polio eradication in Nigeria - authors' reply.

Mangal TD, Aylward RB, Grassly NC.

Lancet Glob Health. 2014 Jun;2(6):e316. doi: 10.1016/S2214-109X(14)70035-X. Epub 2014 May 21. No abstract available.

14.

The role of older children and adults in wild poliovirus transmission.

Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, Wassilak S, Aylward RB, Grassly NC.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10604-9. doi: 10.1073/pnas.1323688111. Epub 2014 Jul 7.

15.

Polio in syria.

Aylward RB, Alwan A.

Lancet. 2014 Feb 8;383(9916):489-91. doi: 10.1016/S0140-6736(14)60132-X. Epub 2014 Jan 31. No abstract available.

PMID:
24491482
16.

The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting.

Mangal TD, Aylward RB, Grassly NC.

Am J Epidemiol. 2013 Nov 15;178(10):1579-87. doi: 10.1093/aje/kwt203. Epub 2013 Oct 7.

PMID:
24100955
17.

Priming after a fractional dose of inactivated poliovirus vaccine.

Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, Garcia G, Fonseca M, Hung LH, Kahn AL, Burton A, Landaverde JM, Aylward RB.

N Engl J Med. 2013 Jan 31;368(5):416-24. doi: 10.1056/NEJMoa1202541.

18.

The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.

O'Reilly KM, Durry E, ul Islam O, Quddus A, Abid N, Mir TP, Tangermann RH, Aylward RB, Grassly NC.

Lancet. 2012 Aug 4;380(9840):491-8. doi: 10.1016/S0140-6736(12)60648-5. Epub 2012 Jul 4.

19.

Waning intestinal immunity after vaccination with oral poliovirus vaccines in India.

Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, Wolff C, Sutter RW, Aylward RB.

J Infect Dis. 2012 May 15;205(10):1554-61. doi: 10.1093/infdis/jis241. Epub 2012 Mar 23.

PMID:
22448007
20.

Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.

Estívariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, Awale J, Burton A, Bahl S, Chatterjee A, Aylward RB.

Lancet Infect Dis. 2012 Feb;12(2):128-35. doi: 10.1016/S1473-3099(11)70190-6. Epub 2011 Nov 7.

PMID:
22071249
21.

A statistical model of the international spread of wild poliovirus in Africa used to predict and prevent outbreaks.

O'Reilly KM, Chauvin C, Aylward RB, Maher C, Okiror S, Wolff C, Nshmirimana D, Donnelly CA, Grassly NC.

PLoS Med. 2011 Oct;8(10):e1001109. doi: 10.1371/journal.pmed.1001109. Epub 2011 Oct 18.

22.

Economic analysis of the global polio eradication initiative.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM.

Vaccine. 2010 Dec 16;29(2):334-43. doi: 10.1016/j.vaccine.2010.10.026. Epub 2010 Oct 26.

PMID:
21029809
23.

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.

Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB.

Lancet. 2010 Nov 13;376(9753):1682-8. doi: 10.1016/S0140-6736(10)61230-5. Epub 2010 Oct 25.

PMID:
20980048
24.

Implications of a circulating vaccine-derived poliovirus in Nigeria.

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC.

N Engl J Med. 2010 Jun 24;362(25):2360-9. doi: 10.1056/NEJMoa0910074. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

25.

Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.

Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB.

J Infect Dis. 2009 Sep 1;200(5):794-801. doi: 10.1086/605330.

PMID:
19624278
26.

Effectiveness of immunization against paralytic poliomyelitis in Nigeria.

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, Grassly NC.

N Engl J Med. 2008 Oct 16;359(16):1666-74. doi: 10.1056/NEJMoa0803259.

27.

The risks, costs, and benefits of possible future global policies for managing polioviruses.

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE Jr, Alexander J, Jafari H, Cochi SL.

Am J Public Health. 2008 Jul;98(7):1322-30. doi: 10.2105/AJPH.2007.122192. Epub 2008 May 29.

28.

Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study.

Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB.

Lancet. 2007 Apr 21;369(9570):1356-1362. doi: 10.1016/S0140-6736(07)60531-5. Erratum in: Lancet. 2007 May 26;369(9575):1790.

PMID:
17448821
29.

Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL.

Risk Anal. 2006 Dec;26(6):1571-80.

PMID:
17184398
30.

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM.

Risk Anal. 2006 Dec;26(6):1471-505.

PMID:
17184393
31.

New strategies for the elimination of polio from India.

Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, Heymann DL, Aylward RB.

Science. 2006 Nov 17;314(5802):1150-3.

32.

Mass vaccination: when and why.

Heymann DL, Aylward RB.

Curr Top Microbiol Immunol. 2006;304:1-16. Review.

PMID:
16989261
33.

Eradicating polio: today's challenges and tomorrow's legacy.

Aylward RB.

Ann Trop Med Parasitol. 2006 Jul-Sep;100(5-6):401-13. Review.

PMID:
16899145
35.

A vision of a world without polio: the OPV cessation strategy.

Heymann DL, Sutter RW, Aylward RB.

Biologicals. 2006 Jun;34(2):75-9. Epub 2006 May 8.

PMID:
16682224
36.

Interrupting poliovirus transmission -- new solutions to an old problem.

Aylward RB, Maher C.

Biologicals. 2006 Jun;34(2):133-9. Epub 2006 May 8.

PMID:
16682220
37.

Poliomyelitis eradication and pandemic influenza.

Heymann DL, Aylward RB.

Lancet. 2006 May 6;367(9521):1462-4. No abstract available.

PMID:
16679142
38.

The human story.

Aylward RB, Birmingham M.

BMJ. 2005 Nov 26;331(7527):1261-2. Review. No abstract available.

39.

Policy. OPV cessation--the final step to a "polio-free" world.

Aylward RB, Sutter RW, Heymann DL.

Science. 2005 Oct 28;310(5748):625-6.

PMID:
16254173
40.

Polio eradication: mobilizing and managing the human resources.

Aylward RB, Linkins J.

Bull World Health Organ. 2005 Apr;83(4):268-73. Epub 2005 Apr 25.

41.
42.

A global call for new polio vaccines.

Heymann DL, Sutter RW, Aylward RB.

Nature. 2005 Apr 7;434(7034):699-700. No abstract available.

PMID:
15815604
43.

Protecting investments in polio eradication: the past, present and future of surveillance for acute flaccid paralysis.

Heymann DL, De Gourville EM, Aylward RB.

Epidemiol Infect. 2004 Oct;132(5):779-80. No abstract available.

44.

Eradicating polio.

Heymann DL, Aylward RB.

N Engl J Med. 2004 Sep 23;351(13):1275-7. No abstract available.

45.

Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free world.

Heymann DL, Aylward RB, Wolff C.

Lancet. 2004 May 15;363(9421):1566-8. No abstract available.

PMID:
15145625
46.
47.

Global health goals: lessons from the worldwide effort to eradicate poliomyelitis.

Aylward RB, Acharya A, England S, Agocs M, Linkins J.

Lancet. 2003 Sep 13;362(9387):909-14. Review.

PMID:
13678981
48.

Possible global strategies for stopping polio vaccination and how they could be harmonized.

Cochi SL, Sutter RW, Aylward RB.

Dev Biol (Basel). 2001;105:153-8; discussion 159.

PMID:
11763323
49.

The global polio eradication initiative.

Maher D, Aylward RB.

Trop Doct. 2001 Oct;31(4):246-8. Review. No abstract available.

PMID:
11676075
50.

Progress towards global polio eradication.

Hull HF, Aylward RB.

Vaccine. 2001 Aug 14;19(31):4378-84. Review.

PMID:
11483262

Supplemental Content

Loading ...
Support Center